Latest Commercialisation News

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Clarity Pharmaceuticals reports that its Cu-SARTATE diagnostic agent significantly outperforms the current standard in detecting neuroendocrine tumours, paving the way for a pivotal Phase III study.

State Gas Limited has settled a land access dispute at its Rolleston West Project, enabling the company to resume drilling and flow testing activities. This development paves the way for advancing coal seam gas production using innovative technologies.

Proteomics International has published clinical validation results for PromarkerEso, a novel blood test that detects esophageal adenocarcinoma with remarkable accuracy, promising a non-invasive alternative to costly and uncomfortable endoscopy procedures.

Sparc Technologies has successfully closed its Share Purchase Plan, raising more than double its initial target, signaling strong shareholder confidence as it advances its green hydrogen and graphene projects.

Nimy Resources reports promising signs of a large, continuous gallium mineralised system at its Block 3 Gallium Project in Western Australia, with drilling confirming key host rocks over 1.5 kilometres of strike. Assay results are imminent as the company advances exploration and metallurgical testing.

Proteomics International has completed a $12 million capital raise, including a heavily oversubscribed Share Purchase Plan, to fast-track the rollout of its innovative diagnostic tests in Australia and the USA.

Wide Open Agriculture Ltd has announced a Share Purchase Plan aiming to raise up to $500,000 through the issue of new shares and free-attaching options, pending shareholder approval. This capital raise complements a recent $2.6 million placement to support the company’s growth and production ramp-up.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

New Frontier Minerals Ltd highlights significant exploration progress at its Harts Range heavy rare earths project and the NWQ Copper Project, backed by strategic partnerships and promising assay results.

Pursuit Minerals has dispatched high-purity lithium carbonate samples from its Argentine pilot plant to potential partners, advancing feasibility studies for a 5,000tpa operation while exploring strategic acquisitions in precious and base metals.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.